Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18840369,"Cmax,ss ratio","The Cmax,ss ratio was 111 (90% CI, 91-136) and area under the plasma concentration-time curve during a dosing interval (AUC0-tau) ratio had a value of 103 (90% CI, 91-117).","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,111,17539,DB00967,Desloratadine
,18840369,"Cmax,ss ratios","Point estimates for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,111,17540,DB00967,Desloratadine
,18840369,"Cmax,ss ratios","Point estimates for Cmax,ss ratios using paired data were 111% for rupatadine, 109% for desloratadine, and 109% for 3-hydroxydesloratadine.","Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840369/),,109,17541,DB00967,Desloratadine
,16059990,ú,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,1.611,28489,DB00967,Desloratadine
,16059990,t(max),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,1.611,28490,DB00967,Desloratadine
,16059990,C(max),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [l],4.455,28491,DB00967,Desloratadine
,16059990,AUC(0-t),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [h·l],58.50,28492,DB00967,Desloratadine
,16059990,AUC(0-infinity),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[μg] / [h·l],60.59,28493,DB00967,Desloratadine
,16059990,t(1/2(ke)),"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,20.303,28494,DB00967,Desloratadine
,16059990,Ke,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),1/[h],0.0372,28495,DB00967,Desloratadine
,16059990,CL,"The main pharmacokinetics parameters of desloratadine tablets were as followsút(max)(1.611 +/-0.366)h, C(max) (4.455+/-1.990)microg x L(-1), AUC(0-t) (58.50+/-21.34)microg x L(-1) x h(-1), AUC(0-infinity) (60.59+/-22.32)microg x L(-1) x h(-1), t(1/2(ke)) (20.303+/-5.833)h, Ke (0.0372+/-0.0116)h(-1) and CL(0.1838+/-0.0563)L x h(-1).",[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),[l] / [h],0.1838,28496,DB00967,Desloratadine
,16059990,t(1/2),Desloratadine tablet is absorbed quicker in the 18 healthy volunteers than the reports and its peak blood concentration reached at 1.5 h after oral administration with t(1/2) 20 h.,[Study on determination of desloratadine in human serum and its pharmacokinetics by HPLC/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16059990/),h,20,28497,DB00967,Desloratadine
,12584158,efflux ratio,"Likewise, the efflux ratio between basolateral to apical and apical to basolateral was 4.6- and 6.6-fold higher in MDR1-MDCK than the parental MDCK for certirizine and desloratadine, respectively, whereas it was approximately 1 for diphenhydramine and triprolidine.",P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12584158/),,1,47722,DB00967,Desloratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],27.8,53003,DB00967,Desloratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],35.5,53004,DB00967,Desloratadine
,17324243,apparent clearance (CL/F),"The apparent clearance (CL/F) of desloratadine, population estimate (%CV), in children aged > or =6 months- <1 year was 27.8 l h(-1) (35) and corresponding values in children > or =1 year- < or =2 years was 35.5 l h(-1) (51), compared with 137 l h(-1) (58) for adults.",Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17324243/),[l] / [h],137,53005,DB00967,Desloratadine
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,6.47,53647,DB00967,Desloratadine
,31338198,H1ROs,"Brain H1ROs after desloratadine and loratadine administration were 6.47 ± 10.5% and 13.8 ± 7.00%, respectively (P = 0.103).",Brain histamine H1 receptor occupancy after oral administration of desloratadine and loratadine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31338198/),%,13.8,53648,DB00967,Desloratadine
,2966185,plasma Cmax,"For loratadine, the plasma Cmax was 30.5 ng/mL at 1.0 hour after dosing and the milk Cmax was 29.2 ng/mL in the 0 to 2 hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],30.5,61371,DB00967,Desloratadine
,2966185,Cmax,"For loratadine, the plasma Cmax was 30.5 ng/mL at 1.0 hour after dosing and the milk Cmax was 29.2 ng/mL in the 0 to 2 hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],29.2,61372,DB00967,Desloratadine
,2966185,milk-plasma AUC ratio,"Through 48 hours, the loratadine milk-plasma AUC ratio was 1.2 and 4.2 micrograms of loratadine was excreted in breast milk, which was 0.010% of the administered dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,1.2,61373,DB00967,Desloratadine
,2966185,milk-plasma AUC ratio,"Through 48 hours, the loratadine milk-plasma AUC ratio was 1.2 and 4.2 micrograms of loratadine was excreted in breast milk, which was 0.010% of the administered dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,4.2,61374,DB00967,Desloratadine
,2966185,plasma,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],18.6,61375,DB00967,Desloratadine
,2966185,Cmax,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],18.6,61376,DB00967,Desloratadine
,2966185,Cmax,"For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval.",Excretion of loratadine in human breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),[ng] / [ml],16.0,61377,DB00967,Desloratadine
,2966185,AUC ratio,"Through 48 hours, the mean milk-plasma descarboethoxyloratadine AUC ratio was 0.8 and a mean of 6.0 micrograms of descarboethoxyloratadine (7.5 micrograms loratadine equivalents) were excreted in the breast milk, or 0.019% of the administered loratadine dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),,0.8,61378,DB00967,Desloratadine
,2966185,AUC ratio,"Through 48 hours, the mean milk-plasma descarboethoxyloratadine AUC ratio was 0.8 and a mean of 6.0 micrograms of descarboethoxyloratadine (7.5 micrograms loratadine equivalents) were excreted in the breast milk, or 0.019% of the administered loratadine dose.",Excretion of loratadine in human breast milk. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2966185/),μg,6.0,61379,DB00967,Desloratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],7.17,65340,DB00967,Desloratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],11.06,65341,DB00967,Desloratadine
,15932952,oral clearance,"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),[l] / [h·kg],14.59,65342,DB00967,Desloratadine
,15932952,area under the plasma concentration-time curve (AUC),"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),,1.55,65343,DB00967,Desloratadine
,15932952,area under the plasma concentration-time curve (AUC),"In comparing homozygous CYP2D6*10 (group III) to heterozygous CYP2D6*10 (group II) to homozygous CYP2D6*1 (group I) subjects, loratadine oral clearance values were 7.17+/- 2.54 versus 11.06+/-1.70 versus 14.59+/-2.43 l/h/kg, respectively [one-way analysis of variance (ANOVA), p<0.01], and the corresponding metabolic ratios [area under the plasma concentration-time curve (AUC)(desloratadine)/AUC(loratadine)] were 1.55+/-0.73 versus 2.47+/- 0.46 versus 3.32+/- 0.49, respectively (one-way ANOVA, p<0.05), indicating a gene-dose effect.",Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932952/),,3.32,65344,DB00967,Desloratadine
,29403740,flow rate,"Chromatographic separation was performed using an Xbridge C18 column (50 mm×4.6 mm, 5 μm) with an isocratic mobile phase composed of 10 mM ammonium formate: methanol (20:80, v/v), at a flow rate of 0.7 mL/min.",Quantification of desloratadine in human plasma by LC-ESI-MS/MS and application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403740/),[ml] / [min],0.7,87121,DB00967,Desloratadine
,17620222,t((1/2)),"In five of the six subjects, DL was slowly eliminated (mean t((1/2)) = 19.5 h) and persisted in the plasma for 48-120 h post-dose.",Disposition of desloratadine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620222/),h,19.5,95646,DB00967,Desloratadine
,17620222,t((1/2)),"This is in contrast to a t((1/2)) of approximately 110 h and quantifiable plasma DL concentrations for the entire 240-h sampling period in one subject, who was identified phenotypically as a poor metabolizer of DL.",Disposition of desloratadine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17620222/),h,110,95647,DB00967,Desloratadine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,431,98418,DB00967,Desloratadine
,12169045,maximum corrected QT (QT(c)) intervals,"Comparable maximum corrected QT (QT(c)) intervals were observed after coadministration of desloratadine and placebo or ketoconazole (431 and 435 msec, respectively).",Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169045/),ms,435,98419,DB00967,Desloratadine
,15019035,flow rate,"Chromatographic separation was performed on a Hypersil CN column (150 mm x 5.0 mm, 5 microm) using a mixture of methanol, acetonitrile and phosphate buffer (pH 5.5; 0.01 mol/l) (35:35:30, v/v/v) as mobile phase delivered at a flow rate of 0.8 ml/min.",High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019035/),[ml] / [min],0.8,102129,DB00967,Desloratadine
,15019035,recovery,The recovery of desloratadine from dog plasma ranged from 78.8 to 82.0%.,High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15019035/),%,78.8 to 82.0,102130,DB00967,Desloratadine
,17156962,extraction efficiencies,The extraction efficiencies were approximately 70% and recoveries of method ranged from 98.53 to 103.24%.,Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156962/),%,70,107736,DB00967,Desloratadine
,17156962,recoveries,The extraction efficiencies were approximately 70% and recoveries of method ranged from 98.53 to 103.24%.,Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17156962/),%,98.53 to 103.24,107737,DB00967,Desloratadine
≥,26446005,half-life (t 1/2),The individuals with a 3-OH-desloratadine-to-desloratadine exposure ratio lower than 10 % or a desloratadine half-life (t 1/2) of ≥50 h were supposed to be DSM.,Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446005/),h,50,108420,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,5.62,117071,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,4.08,117072,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,4.29,117073,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),h,2.6,117074,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),,3.26,117075,DB00967,Desloratadine
,18622814,t1/2,"However, the elimination half-life (t1/2) of the parent compound and its metabolite was significantly longer (p<0.01) following administration at 9 HALO (t1/2 loratadine and desloratadine 5.62 and 4.08 h at 9 HALO vs. 4.29 and 2.6 h at 17 HALO vs. 3.26 and 3.27 at 1 HALO).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),,3.27,117076,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],133.05,117077,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],258.07,117078,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],104.5,117079,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],188.62,117080,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],94.33,117081,DB00967,Desloratadine
,18622814,C(max),There were relevant (p<0.05) differences in C(max) between the three treated groups for loratadine and desloratadine; 133.05+/-3.55 and 258.07+/-14.45 ng/mL at 9 HALO vs. 104.5+/-2.61 and 188.62+/-7.20 ng/mL at 1 HALO vs. 94.33+/-20 and 187.75+/-10.79 ng/mL at 17 HALO.,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],187.75,117082,DB00967,Desloratadine
,18622814,total apparent clearance,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],61.46,117083,DB00967,Desloratadine
,18622814,total apparent clearance,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],15.97,117084,DB00967,Desloratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],57.3,117085,DB00967,Desloratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],14.22,117086,DB00967,Desloratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],43.79,117087,DB00967,Desloratadine
,18622814,CL,"Drug dosing at 17 HALO resulted in highest loratadine and desloratadine total apparent clearance values: 61.46 and 15.97 L/h/kg, respectively, whereas loratadine and desloratadine clearances (CL) were significantly slower (p<0.05) at the other administration times (loratadine and desloratadine CL was 57.3 and 14.22 L/h/kg at 1 HALO vs. 43.79 and 12.89 L/h/kg at 9 HALO, respectively).",Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[l] / [h·kg],12.89,117088,DB00967,Desloratadine
,18622814,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of loratadine and desloratadine was significantly (p<0.05) greater following drug administration at 9 HALO (456.75 and 1550.57 (ng/mL) .,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],456.75,117089,DB00967,Desloratadine
,18622814,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) of loratadine and desloratadine was significantly (p<0.05) greater following drug administration at 9 HALO (456.75 and 1550.57 (ng/mL) .,Circadian time-effect of orally administered loratadine on plasma pharmacokinetics in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622814/),[ng] / [ml],1550.57,117090,DB00967,Desloratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.17,126203,DB00967,Desloratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.68,126204,DB00967,Desloratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.87,126205,DB00967,Desloratadine
,12169043,C(max),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],5.00,126206,DB00967,Desloratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],77.9,126207,DB00967,Desloratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],80.0,126208,DB00967,Desloratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],90.6,126209,DB00967,Desloratadine
,12169043,AUC from 0 to 24 hours (AUC(24h)),"Following multiple doses, the geometric mean C(max) was 5.17 microg/L in men, 5.68 microg/L in women, 5.87 microg/L in Black participants and 5.00 microg/L in White participants; the corresponding AUC from 0 to 24 hours (AUC(24h)) values were 77.9, 80.0, 90.6 and 68.8 micro g/L x h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],68.8,126210,DB00967,Desloratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],1.93,126211,DB00967,Desloratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.79,126212,DB00967,Desloratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.20,126213,DB00967,Desloratadine
,12169043,C(max),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [l],2.45,126214,DB00967,Desloratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],32.1,126215,DB00967,Desloratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],47.5,126216,DB00967,Desloratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],37.1,126217,DB00967,Desloratadine
,12169043,AUC(24h),"Corresponding 3-OH desloratadine geometric mean C(max) values were 1.93, 2.79, 2.20 and 2.45 microg/L, and the AUC(24h) values were 32.1, 47.5, 37.1 and 41.1 microg/L. h.",Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169043/),[μg] / [h·l],41.1,126218,DB00967,Desloratadine
,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,0.9,129595,DB00967,Desloratadine
> or =,15312146,time required to reach peak plasma levels (tmax),The time required to reach peak plasma levels (tmax) is shortest for levocetirizine (0.9 h) and longest for desloratadine (> or =3 h).,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),h,3,129596,DB00967,Desloratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],0.4,129597,DB00967,Desloratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],1-1.2,129598,DB00967,Desloratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],5.4-5.8,129599,DB00967,Desloratadine
,15312146,apparent volume of distribution,"The apparent volume of distribution is limited for levocetirizine (0.4 L/kg) and mizolastine (1-1.2 L/kg), larger for fexofenadine (5.4-5.8 L/kg) and particularly large for desloratadine (approximately 49 l/kg).","Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),[l] / [kg],49,129600,DB00967,Desloratadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,50-65,129601,DB00967,Desloratadine
,15312146,absolute bioavailability,The absolute bioavailability is 50-65% for mizolastine; it is high for levocetirizine as the percentage of the drug eliminated unchanged in the 48 h urine is 77% of the oral dose; the estimation for fexofenadine is at least 33%; no estimation was found for desloratadine.,"Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312146/),%,33,129602,DB00967,Desloratadine
,11502723,maximal human plasma concentration,"Loratadine did not inhibit CYP1A2 or CYP3A4 at concentrations up to 3829 ng/ml, which is approximately 815-fold greater than the expected maximal human plasma concentration (4.7 +/- 2.7 ng/ml) following the recommended dose of 10 mg/day.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],4.7,132881,DB00967,Desloratadine
,11502723,IC(50),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,0.76,132882,DB00967,Desloratadine
,11502723,IC(50),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],291,132883,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,0.61,132884,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],234,132885,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,8.1,132886,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],3100,132887,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),μM,2.7,132888,DB00967,Desloratadine
,11502723,K(i),"Loratadine inhibited CYP2C19 and CYP2D6 with IC(50) values of approximately 0.76 microM [291 ng/ml; K(i) congruent with 0.61 microM (234 ng/ml)] and 8.1 microM [3100 ng/ml; K(i) congruent with 2.7 microM (1034 ng/ml)], respectively, which are approximately 62 and 660 times the expected loratadine therapeutic exposure concentration.","In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11502723/),[ng] / [ml],1034,132889,DB00967,Desloratadine
,10868558,peak plasma concentrations,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[ng] / [ml],7.78,143825,DB00967,Desloratadine
,10868558,peak plasma concentrations,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[ng] / [ml],5.09,143826,DB00967,Desloratadine
,10868558,areas under the plasma concentration-time curve to the last quantifiable time point,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[h·ng] / [ml],16.7,143827,DB00967,Desloratadine
,10868558,areas under the plasma concentration-time curve to the last quantifiable time point,"The peak plasma concentrations of loratadine and desloratadine were 7.78 and 5.09 ng/mL, respectively, observed 1.17 and 2.33 hours after administration of loratadine; the areas under the plasma concentration-time curve to the last quantifiable time point for loratadine and desloratadine were 16.7 and 87.2 ng x h/mL, respectively.","The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10868558/),[h·ng] / [ml],87.2,143828,DB00967,Desloratadine
,11243504,half-life,"Desloratadine has a half-life of 21-24 h, permitting once-daily dosing.",The pharmacologic profile of desloratadine: a review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11243504/),h,21-24,148009,DB00967,Desloratadine
,12169041,Maximum mean plasma concentration (C(max)),Maximum mean plasma concentration (C(max)) was 3.53 microg/L in fed compared with 3.30 microg/L in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [l],3.53,149724,DB00967,Desloratadine
,12169041,Maximum mean plasma concentration (C(max)),Maximum mean plasma concentration (C(max)) was 3.53 microg/L in fed compared with 3.30 microg/L in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [l],3.30,149725,DB00967,Desloratadine
,12169041,Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)),Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)) mean values were 61.0 microg/L x h in fed and 61.9 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],61.0,149726,DB00967,Desloratadine
,12169041,Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)),Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)) mean values were 61.0 microg/L x h in fed and 61.9 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],61.9,149727,DB00967,Desloratadine
,12169041,AUC extrapolated to infinity (AUC(infinity )),Fed individuals had mean AUC extrapolated to infinity (AUC(infinity )) of 62.5 microg/L x h compared with 63.5 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],62.5,149728,DB00967,Desloratadine
,12169041,AUC extrapolated to infinity (AUC(infinity )),Fed individuals had mean AUC extrapolated to infinity (AUC(infinity )) of 62.5 microg/L x h compared with 63.5 microg/L x h in fasted participants.,Oral bioavailability of desloratadine is unaffected by food. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169041/),[μg] / [h·l],63.5,149729,DB00967,Desloratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [l],3.98,155843,DB00967,Desloratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [l],1.99,155844,DB00967,Desloratadine
,12169042,Peak plasma concentrations (C(max)),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,3.17,155845,DB00967,Desloratadine
,12169042,t(max),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,3.17,155846,DB00967,Desloratadine
,12169042,t(max),"Peak plasma concentrations (C(max)) of desloratadine (mean 3.98 micro g/L) and 3-OH desloratadine (mean 1.99 micro g/L) were reached at a mean of 3.17 and 4.76 hours (t(max)), respectively, after administration.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,4.76,155847,DB00967,Desloratadine
,12169042,area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)),The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 micro g/L x h for desloratadine and 32.3 micro g/L x h for 3-OH desloratadine.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [h·l],56.9,155848,DB00967,Desloratadine
,12169042,area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)),The area under the plasma concentration-time curve from 0 to 24 hours (AUC(24h)) was 56.9 micro g/L x h for desloratadine and 32.3 micro g/L x h for 3-OH desloratadine.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),[μg] / [h·l],32.3,155849,DB00967,Desloratadine
,12169042,half-lives (t((1/2))),"The mean half-lives (t((1/2))) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,26.8,155850,DB00967,Desloratadine
,12169042,half-lives (t((1/2))),"The mean half-lives (t((1/2))) of desloratadine and 3-OH desloratadine were 26.8 and 36 hours, respectively.","A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,36,155851,DB00967,Desloratadine
,12169042,half-life,The 27-hour half-life of desloratadine permits once daily administration.,"A pharmacokinetic profile of desloratadine in healthy adults, including elderly. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169042/),h,27,155852,DB00967,Desloratadine
,14520518,wheal area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),mm(2),79.3,158644,DB00967,Desloratadine
,14520518,flare area,"Following placebo administration, the mean (+/- SEM) wheal area at 10 min was 79.3 +/- 6.9 mm(2), mean flare area for the first 5 min following challenge 26.6 +/- 2.7 cm(2), and itch score for the same period 48.5 +/- 7.6%.","Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520518/),cm(2),26.6,158645,DB00967,Desloratadine
,12169040,half-life (t((1/2))),The half-life (t((1/2))) ranged from 21.2 to 24.1 hours.,Desloratadine demonstrates dose proportionality in healthy adults after single doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169040/),h,21.2 to 24.1,163902,DB00967,Desloratadine
,12852841,maximum concentration (C(max)),Mean maximum concentration (C(max)) was found (17+/-14) microg/L for LOR at 1.2 h and (16+/-9) microg/L for DCL at 1.5 h.,Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[μg] / [l],17,191038,DB00967,Desloratadine
,12852841,maximum concentration (C(max)),Mean maximum concentration (C(max)) was found (17+/-14) microg/L for LOR at 1.2 h and (16+/-9) microg/L for DCL at 1.5 h.,Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[μg] / [l],16,191039,DB00967,Desloratadine
,12852841,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),"Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was (47+/-49) microg x h x L(-1) for LOR and (181+/-122) microg x h x L(-1) for DCL, respectively.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[h·μg] / [l],47,191040,DB00967,Desloratadine
,12852841,area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)),"Mean area under the plasma concentration-time curve from zero to infinity (AUC(0-infinity)) was (47+/-49) microg x h x L(-1) for LOR and (181+/-122) microg x h x L(-1) for DCL, respectively.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),[h·μg] / [l],181,191041,DB00967,Desloratadine
,12852841,apparent elimination half-life (T1/2),"The apparent elimination half-life (T1/2) of LOR was (6+/-4) h, and that of DCL was (13.4+/-2.6) h.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),h,6,191042,DB00967,Desloratadine
,12852841,apparent elimination half-life (T1/2),"The apparent elimination half-life (T1/2) of LOR was (6+/-4) h, and that of DCL was (13.4+/-2.6) h.",Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852841/),h,13.4,191043,DB00967,Desloratadine
,12169044,maximum corrected QT (QT(c)) interval,The maximum corrected QT (QT(c)) interval was 445 msec for both treatments.,Lack of clinically relevant interaction between desloratadine and erythromycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12169044/),ms,445,203340,DB00967,Desloratadine
,17488362,C(max),Plasma desloratadine C(max) occurred at a median of 2.0 h after dosing in both age groups.,Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,2.0,225579,DB00967,Desloratadine
,17488362,t(1/2),"Arithmetic (and harmonic) mean t(1/2) (h) values for each group, respectively, were 16.4 (13.9) and 19.4 (15.8).",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,16.4,225580,DB00967,Desloratadine
,17488362,t(1/2),"Arithmetic (and harmonic) mean t(1/2) (h) values for each group, respectively, were 16.4 (13.9) and 19.4 (15.8).",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),h,19.4,225581,DB00967,Desloratadine
,17488362,AUC(last),"Exposure to desloratadine was similar in both the younger and older age groups, with a median AUC(last) of 38.8 and 38.2 ng ml(-1) h, respectively.",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),[h·ng] / [ml],38.8,225582,DB00967,Desloratadine
,17488362,AUC(last),"Exposure to desloratadine was similar in both the younger and older age groups, with a median AUC(last) of 38.8 and 38.2 ng ml(-1) h, respectively.",Pharmacokinetics of desloratadine in children between 2 and 11 years of age. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488362/),[h·ng] / [ml],38.2,225583,DB00967,Desloratadine
,11295678,half-life,"Desloratadine is rapidly absorbed, has dose-proportional pharmacokinetics, and has a half-life of 27 hours.","Desloratadine: A new, nonsedating, oral antihistamine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295678/),h,27,230937,DB00967,Desloratadine
,20819087,maximal plasma levels,"Rupatadine 40 mg reached maximal plasma levels of 15·1 ± 4·4 ng mL⁻¹)1 at 1 h and its metabolite, desloratadine, 5·2 ± 0·9 ng mL⁻¹)1 at 2 h.",Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20819087/),ml⁻¹)·ng,15·1,241088,DB00967,Desloratadine
,20819087,maximal plasma levels,"Rupatadine 40 mg reached maximal plasma levels of 15·1 ± 4·4 ng mL⁻¹)1 at 1 h and its metabolite, desloratadine, 5·2 ± 0·9 ng mL⁻¹)1 at 2 h.",Efficacy and tolerability of rupatadine at four times the recommended dose against histamine- and platelet-activating factor-induced flare responses and ex vivo platelet aggregation in healthy males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20819087/),ml⁻¹)·ng,5·2,241089,DB00967,Desloratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,12.21,248271,DB00967,Desloratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.39-17.03,248272,DB00967,Desloratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,10.68,248273,DB00967,Desloratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,6.96,248274,DB00967,Desloratadine
,15752381,QTc,"Mean QTc was statistically significantly increased during both ebastine/ketoconazole administration (12.21 ms; 7.39-17.03 ms) and loratadine/ketoconazole administration (10.68 ms; 6.15-15.21 ms) but these changes were not statistically significantly different from the increases seen with placebo/ketoconazole (6.96 ms; 3.31-10.62 ms), P = 0.08 ebastine study, (7.52 ms; 4.15-10.89 ms), P = 0.26 loratadine study).",Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752381/),ms,7.52,248275,DB00967,Desloratadine
,17497754,flow rate,The mobile phase containing sodium dodecyl sulfate (SDS) as ion pairing agent was pumped at a flow rate of 1 mL/min.,Validated ion pair liquid chromatography/fluorescence detection method for assessing the variability of the loratadine metabolism occurring in bioequivalence studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17497754/),[ml] / [min],1,257365,DB00967,Desloratadine
,2965043,maximum plasma concentration,"Loratadine was rapidly absorbed, reaching a maximum plasma concentration of 50.5 ng/ml at 1.5 h after dosing.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[ng] / [ml],50.5,261832,DB00967,Desloratadine
,2965043,disposition half-lives,"The disposition half-lives of loratadine in the distribution and elimination phases were 1.5 and 18.2 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,1.5,261833,DB00967,Desloratadine
,2965043,disposition half-lives,"The disposition half-lives of loratadine in the distribution and elimination phases were 1.5 and 18.2 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,18.2,261834,DB00967,Desloratadine
,2965043,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve, was 146.7 h.ng/ml.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[h·ng] / [ml],146.7,261835,DB00967,Desloratadine
,2965043,maximum plasma concentration,Descarboethoxyloratadine had a maximum plasma concentration of 28.0 ng/ml at 2.9 h post-dose and an area under the concentration-time curve of 394.9 h.ng/ml.,The pharmacokinetics of loratadine in normal geriatric volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[ng] / [ml],28.0,261836,DB00967,Desloratadine
,2965043,area under the concentration-time curve,Descarboethoxyloratadine had a maximum plasma concentration of 28.0 ng/ml at 2.9 h post-dose and an area under the concentration-time curve of 394.9 h.ng/ml.,The pharmacokinetics of loratadine in normal geriatric volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),[h·ng] / [ml],394.9,261837,DB00967,Desloratadine
,2965043,disposition half-lives,"Its disposition half-lives in the distribution and elimination phases were 2.8 and 17.4 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,2.8,261838,DB00967,Desloratadine
,2965043,disposition half-lives,"Its disposition half-lives in the distribution and elimination phases were 2.8 and 17.4 h, respectively.",The pharmacokinetics of loratadine in normal geriatric volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2965043/),h,17.4,261839,DB00967,Desloratadine
≥,22271705,half-life,Poor metabolizers or slow metabolizers of desloratadine were determined as individuals having a 3-OH-desloratadine to desloratadine exposure ratio lower than 10% or a desloratadine half-life ≥ 50 h.,Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271705/),h,50,262296,DB00967,Desloratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,8.7,265049,DB00967,Desloratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,7.6,265050,DB00967,Desloratadine
,2140371,t1/2 beta,"No significant differences in t1/2 beta were observed between the three groups (8.7 +/- 5.9, 7.6 +/- 6.9, 8.6 +/- 1.6 hrs: in groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),h,8.6,265051,DB00967,Desloratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],212.4,265052,DB00967,Desloratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],469.5,265053,DB00967,Desloratadine
,2140371,AUC infinity 0,"The metabolite AUC infinity 0 however was significantly greater in group II subjects: (212.4 +/- 37.8, 469.5 +/- 95.4, 325.2 +/- 114.6 ng.hr/mL; groups I, II, and III, respectively).",Pharmacokinetics of loratadine in patients with renal insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2140371/),[h·ng] / [ml],325.2,265054,DB00967,Desloratadine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,21,267874,DB00967,Desloratadine
,30630815,AUC0-71 h ratios,"Moreover, the 3-hydroxydesloratadine:desloratadine AUC0-71 h ratios were 21% (P = 7 × 10-10) and 1.7% (P = 8 × 10-11) of control during the clopidogrel and gemfibrozil phases.",Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30630815/),%,1.,267875,DB00967,Desloratadine
